SCHEMBL2114504

SCHEMBL2114504

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCNCCC#N

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.79
PRKAA1 Q13131 8/20 0.79
PRKAA2 P54646 7/20 0.79
TLK2 Q86UE8 3/20 0.79
PDGFRB P09619 11/20 0.73
FGFR1 P11362 7/20 0.73
HDAC3 O15379 4/20 0.72
HDAC4 P56524 4/20 0.72
HDAC1 Q13547 4/20 0.72
HDAC7 Q8WUI4 4/20 0.72
HDAC2 Q92769 4/20 0.72
HDAC10 Q969S8 4/20 0.72
HDAC11 Q96DB2 4/20 0.72
HDAC8 Q9BY41 4/20 0.72
HDAC6 Q9UBN7 4/20 0.72
HDAC9 Q9UKV0 4/20 0.72
HDAC5 Q9UQL6 4/20 0.72
PLK4 O00444 2/20 0.71
DCLK1 O15075 2/20 0.71
PDPK1 O15530 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31672529 1.00 KDR (0.79) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL13755261 0.92 KDR (0.79) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL2116631 0.90 KDR (0.71) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL31672507 0.90 KDR (0.71) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL2116175 0.90 KDR (0.71) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL31672444 0.90 KDR (0.75) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL2114517 0.90 KDR (0.75) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL31672460 0.90 KDR (0.71) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL13755277 0.90 KDR (0.85) KDRPRKAA1PRKAA2TLK2PDGFRB
SCHEMBL4453225 0.89 KDR (1.00) KDRPRKAA1PRKAA2TLK2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-04-19 US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK KDR 395/4885PRKAA1 881/4885PRKAA2 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.